Plasma lipidomic analysis to investigate putative biomarkers of P‐glycoprotein activity in healthy volunteers
Clinical and Translational Science · 2023
DOI: 10.1111/cts.13601 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2023. Verfasst von Théodore Decaix und 11 weiteren Autor:innen. Beteiligte Einrichtung: CNRS, CiTCoM, Paris-Cité University, Paris, France. Hauptthemen laut MEDLINE: Lipidomics, Clarithromycin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
P‐glycoprotein (P‐gp) is an efflux transporter involved in the bioavailability of many drugs currently on the market. P‐gp is responsible for several drug–drug interactions encountered in clinical practice leading to iatrogenic hospital admissions, especially in polypharmacy situations. ABCB1 genotyping only reflects an indirect estimate of P‐gp activity. Therefore, it would be useful to identify endogenous biomarkers to determine the P‐gp phenotype to predict in vivo activity prior to the initiation of treatment and to assess the effects of drugs on P‐gp activity. The objective of this study was to assess changes in plasma lipidome composition among healthy volunteers selected on the basis of their ABCB1 genotype and who received clarithromycin, a known inhibitor of P‐gp. Untargeted lipidomic analysis based on liquid chromatography–tandem mass spectrometry was performed before and after clarithromycin administration. Our results revealed changes in plasma levels of some ceramides (Cers) {Cer(d18:1/22:0), Cer(d18:1/22:1), and Cer(d18:1/20:0) by ~38% ( p < 0.0001), 13% ( p < 0.0001), and 13% ( p < 0.0001), respectively} and phosphatidylcholines (PCs) {PC(17:0/14:1), PC(16:0/18:3), and PC(14:0/18:3) by ~24% ( p < 0.001), 10% ( p < 0.001), and 23.6% ( p < 0.001)} associated with both ABCB1 genotype and clarithromycin intake. Through the examination of plasma lipids, our results highlight the relevance of untargeted lipidomics for studying in vivo P‐gp activity and, more generally, to safely phenotyping transporters.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CNRS, CiTCoM, Paris-Cité University, Paris, France.
- Department of Hematology-Hemostasis, IRSET-INSERM-1085, University Hospital, Rennes, France.
- Clinical Pharmacology Department, University Hospital of Saint-Etienne, Saint Etienne, France.
- INSERM, U1059, Vascular Dysfunction and Hemostasis, Saint-Etienne, France.
- Vascular and Therapeutic Medicine Department, Saint-Etienne University Hospital Center, Saint-Etienne, France.
- Pharmacology Department, APHP, Pitié-Salpétrière Hospital, GHU Sorbonne University, Paris, France.
ORCID-Profile: Théodore Decaix, Joe-Elie Salem, Céline Narjoz
Zitieren
APA
Decaix, T., Magny, R., Gouin-Thibaut, I., Delavenne, X., Mismetti, P., Salem, J. E., Narjoz, C., Blanchard, A., Pépin, M., Auzeil, N., Loriot, M. A., & Laprévote, O. (2023). Plasma lipidomic analysis to investigate putative biomarkers of P‐glycoprotein activity in healthy volunteers. Clinical and Translational Science. https://doi.org/10.1111/cts.13601
Vancouver
Decaix T, Magny R, Gouin-Thibaut I, Delavenne X, Mismetti P, Salem JE, et al. Plasma lipidomic analysis to investigate putative biomarkers of P‐glycoprotein activity in healthy volunteers. Clinical and Translational Science. 2023. doi:10.1111/cts.13601
BibTeX
@article{Decaix2023,
author = {Decaix, Théodore and Magny, Romain and Gouin-Thibaut, Isabelle and Delavenne, Xavier and Mismetti, Patrick and Salem, Joe-Elie and Narjoz, Céline and Blanchard, Anne and Pépin, Marion and Auzeil, Nicolas and Loriot, Marie-Anne and Laprévote, Olivier},
title = {Plasma lipidomic analysis to investigate putative biomarkers of P‐glycoprotein activity in healthy volunteers},
journal = {Clinical and Translational Science},
year = {2023},
doi = {10.1111/cts.13601}
}
EUVIMED